ClinicalTrials.gg
CompletedNCT03895385Updated Sep 17, 2020

A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects

A Phase 1 interventional study of Bimekizumab in Healthy Volunteers, sponsored by UCB Biopharma S.P.R.L.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-17.

Sponsored by UCB Biopharma S.P.R.L. (part of UCB S.A.) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Oct 2019, 7 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of the study is to evaluate whether administration of bimekizumab has an effect on the expected production of antibody titers to the influenza vaccine.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • BKZ
  • UCB4940
  • Healthy Subjects
03

In context

Lead sponsor

UCB Biopharma S.P.R.L. is the lead sponsor of 48 studies on the registry; none are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 12 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is male or female aged ≥18 years and ≤55 years at the Screening Visit
  • Subject must have a blood test with at least two influenza antibody titers ≤1/10 at the Screening Visit and have not developed any flu-like illness 2 weeks before the start of the study
  • Female subjects of must not be lactating and have a negative serum pregnancy test at the Screening Visit, which is confirmed to be negative by urine testing prior to administration of bimekizumab. Female subjects of childbearing potential must agree to use a highly effective method of during the study and for a period of 20 weeks after their last dose of the medicinal product (IMP)
  • Subject has a body weight of ≥45 kg and (BMI) between 18 and 32 kg/m2 (inclusive), at the Screening Visit

Exclusion criteria

Exclusion Criteria:

  • Subject has a known to any of bimekizumab
  • Subject has a history of hypersensitivity to the influenza vaccine
  • Subject is legally institutionalized or has a mental health condition or related care provision (eg, guardianship) that would impede the subject from providing voluntary to participate in the study
  • Female subject who is pregnant, or plans to become pregnant during the study, or lactating, or sexually active with who is not using a medically accepted method
  • Male subjects who are planning a partner pregnancy during the study
  • Subjects receiving vaccination of any kind within the 52 weeks prior to the Screening Visit or the influenza vaccination within 2 years prior to the Screening Visit. are not allowed during the study or for 20 weeks after the last dose of medicinal product (IMP)
  • Subject has a current or past history of gastrointestinal ulceration or other gastrointestinal disease, such as inflammatory bowel disease
  • Subject has an active infection
  • Subject has concurrent acute or chronic viral or C or (HIV) infection or human T-cell lymphotropic virus type-1 (HTLV-1)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Bimekizumab

    Subjects randomized to this arm will receive a single dose bimekizumab followed by inactivated influenza vaccine administered with a prefilled syringe at a predefined time point during the Treatment Period.

    Drug: Bimekizumab

  • No intervention
    No Treatment

    Subjects randomized to this arm will receive the influenza vaccine administered with a prefilled syringe at a predefined time point during the Treatment Period.

Interventions

  • Subjects will receive a single dose bimekizumab at a predefined time point during the Treatment Period.

    Also known as: BKZ, UCB4940

06

What researchers measure

Primary outcomes

  1. Seroconversion response

    A subject is considered as a seroconversion responder if the following is true: subject has either a pre-vaccination HI titer ≤1/10 and a 4-week post-vaccination HI titer ≥1/40 or a pre-vaccination HI titer \>1/10 and a ≥4fold increase in HI titer 4 weeks after vaccination in at least 2 out of 4 serotypes.

    Time frame: From Baseline (Day 1 pre-dose) to 4 weeks post-vaccination (Day 43)

  2. Plasma concentration of bimekizumab (BKZ)

    Bimekizumab plasma concentrations by scheduled sampling time.

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

  3. Incidence of Adverse Events (AE) from Baseline to Safety Follow Up

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: From Baseline to Safety Follow Up (up to Day 140)

Secondary outcomes

  1. Influenza antibody geometric mean titers (GMT)

    Post-vaccination influenza antibody geometric mean titers.

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

  2. Area under the BKZ plasma concentration-time curve over the first 14 days AUC(0-14)

    The AUC(0-14) is the area under the plasma concentration-time curve from time zero to day 14.

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 14)

  3. Area under the BKZ plasma concentration-time curve over the first 28 days AUC(0-28)

    The AUC(0-28) is the area under the plasma concentration-time curve from time zero to day 28.

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 28)

  4. Area under the BKZ plasma concentration-time curve from time zero to last quantifiable concentration (AUCt)

    The AUCt is the area under the plasma concentration-time curve from time zero to last quantifiable concentration (AUCt) of BKZ as determined using the linear trapezoidal rule.

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

  5. Area under the BKZ plasma concentration-time curve from time zero to infinity (AUC)

    The area under the plasma concentration-time curve from time zero to infinity (AUC) of BKZ is calculated as AUC=AUCt+Clast/λz, where Clast is the last quantifiable plasma concentration and λz is the apparent terminal elimination rate constant.

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

  6. Maximum observed BKZ plasma drug concentration (Cmax)

    Cmax is the maximum plasma drug concentration of BKZ observed from pharmacokinetic samples taken at predefined time points.

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

  7. Time of occurrence of the maximum observed BKZ plasma drug concentration (tmax)

    Tmax is the time to reach maximum plasma concentration.

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

  8. Apparent terminal half-life (t1/2)

    Apparent terminal half-life, reported in units of days, as determined via simple linear regression (slope=-λz) of natural log (ln) concentration versus time for data points in the terminal phase of the concentration-time curve. t1/2 is calculated as ln2/λz.

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

07

Study locations

1 site
  • Up0034 001
    San Antonio, Texas 78209, United States
08

References and documents

Individual participant data

Plan to share: No — Due to the small sample size in this trial, IPD cannot be adequately anonymized i.e., there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Oct 2019, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2019
First posted
Mar 29, 2019
StartActual
Apr 2, 2019
Primary completionActual
Oct 4, 2019
CompletionActual
Oct 4, 2019
Last update
Sep 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03895385
Responsible party
Sponsor
First posted
Mar 29, 2019
Start date
Apr 2, 2019
Primary completion
Oct 4, 2019
Completion
Oct 4, 2019
Last update
Sep 17, 2020

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion